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Selumetinib (AZD6244, ARRY-142886) is aMEK1/2 inhibitor that has gained interest as an anti-tumour agent. We have
determined the degree of sensitivity/resistance to Selumetinib in a panel of colorectal cancer cell lines using cell
proliferation and soft agar assays. Sensitive cell lines underwent G1 arrest, whereas Selumetinib had no effect on the
cell cycle of resistant cells. Some of the resistant cell lines showed high levels of ERK1/2 phosphorylation in the
absence of serum. Selumetinib inhibited phosphorylation of ERK1/2 and RSK and had no effect on AKT
phosphorylation in both sensitive and resistant cells. Furthermore, mutations in KRAS, BRAF, or PIK3CA were not
clearly associatedwith Selumetinib resistance. Surprisingly, Selumetinib was able to inhibit phosphorylation of p70 S6
kinase (p70S6K) and its downstream target ribosomal protein S6 (RPS6) in sensitive cell lines. However, p70S6K and
RPS6 phosphorylation remained unaffected or even increased in resistant cells.Moreover, in some of the resistant cell
lines p70S6K and RPS6 were phosphorylated in the absence of serum. Interestingly, colorectal primary cultures
derived from tumours excised to patients exhibited the same behaviour than established cell lines. Pharmacological
inhibition of p70S6K using the PI3K/mTOR inhibitor NVP-BEZ235, the specific mTOR inhibitor Rapamycin and the
specific p70S6K inhibitor PF-4708671 potentiated Selumetinib effects in resistant cells. In addition, biological inhibition
of p70S6K using siRNA rendered responsiveness to Selumetinib in resistant cell lines. Furthermore, combination of
p70S6K silencing andPF-47086714was evenmore effective.Wecan conclude that p70S6K and its downstream target
RPS6 are potential biomarkers of resistance to Selumetinib in colorectal cancer.
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The incidence and mortality rate of colorectal cancer (CRC) have
continued to decline, largely owing to improved screening efforts that
lead to early detection and removal of precancerous polyps and
improvements in anticancer treatment. Despite current therapies,
approximately 40% to 50% of patients with CRC who undergo
potentially curative surgery ultimately relapse and die of metastatic
disease [1]. In addition, approximately 20% of patients with CRC
present metastases (stage IV) at diagnosis, for which palliative
systemic therapy is the primary treatment modality [2].
The RAF/MEK/ERK pathway has attracted much attention in the
search for new chemotherapeutic agents, due to both the high frequency
of KRAS (40%) and BRAF (10%) mutations identified in colon
tumours [3–5] and the essential role of this pathway in promoting cell
proliferation and survival [6]. Moreover, constitutive activation of
ERK1/2 is frequently, though not invariably, observed inCRC cell lines
and primary human tumours derived from colon [7].
MEK1/2 is a central component within the RAF/MEK/ERK
pathway. This kinase harbours a unique inhibitor-binding pocket
next to its ATP binding site that allows for its highly specific
inhibition by small molecules. The binding of an inhibitor to this site
is proposed to lock MEK1/2 into an inactive conformation that
permits binding of ATP and its known substrate, ERK1/2, but alters
the molecular interaction required for catalysis and the access to the
ERK activation loop [8]. Moreover, because the only known target
substrate for MEK1/2 is ERK1/2, and because MEK1/2 is the
exclusive known substrate for B-RAF [9], MEK1/2 represents an
attractive target for chemotherapy. On the contrary, C-RAF (RAF-1)
has effects on a broader range of downstream targets, modulating
apoptosis, cell cycle entry, and angiogenesis. In this way, C-RAF has
evolved into a less efficient MEK kinase, dedicated to the cross talk
and modulation of parallel pathways [10].
Selumetinib (AZD6244, ARRY-142886) is an oral, highly specific,
allosteric inhibitor of MEK1/2 that is currently undergoing clinical
trials [11,12]. It inhibits MEK1 in vitro with an IC50 of 14 nM [13]
and has shown to exert anti-proliferative and pro-apoptotic effects in
various tumour cell lines grown in culture or as xenografts [14].
Binding of Selumetinib to the inhibitor binding pocket of MEK1/2
prevents downstream phosphorylation of ERK1/2 and, thus, inhibits
the RAF/MEK/ERK signalling pathway.
In recent years, there have been great efforts in trying to identify
predictive biomarkers of response to MEK 1/2, including Selumetinib.
To date, studies comprising the identification of molecular biomarkers
toMEK inhibitors treatment remain controversial and despite intensive
studies, the genetic and molecular basis for Selumetinib resistance
remains poorly understood. The main objective of this work was to
determine novel molecular markers of response to Selumetinib
treatment in CRC cell lines and primary cell cultures derived from
tumours excised to patients. With this aim, we analyzed sensitivity to
Selumetinib in a panel of CRC cell lines and classified cell lines as
sensitive or resistant according to their IC50 value. In this work, we
found that resistance, inmost cases, was associated with high basal levels
of phosphorylated p70S6K and RPS6. Furthermore, treatment of
resistant cell lines and primary cultures with Selumetinib did not alter
phosphorylation levels of these proteins. We further show that p70S6K
and RPS6 pharmacological or biological inhibition was able to sensitize
resistant cell lines to Selumetinib. Together, these findings provide a
strong rationale for combination therapies of Selumetinib with p70S6K
and RPS6 inhibitors to tackle resistance in tumours exhibiting highendogenous levels of activated p70S6K and RPS6, or in tumours that
respond to Selumetinib by increasing p70S6K and RPS6 activity.
Materials and Methods
Reagents
Selumetinib and NVP-BEZ235 were obtained from ChemieTek
(Indianapolis, IN). PF-4708671 was purchased from Tocris Bioscience
(Bristol, UK). Propidium iodide, 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT), iodonitrotetrazoluim violet,
and Rapamycin were purchased from Sigma-Aldrich (St. Louis, MO).
Cell Culture
Human colorectal cancer cell lines were obtained from the
American Type Culture Collection (Manassas, VA), except for
HGUE-C-1 cells which were derived from ascites of a patient with
CRC at the Hospital General Universitario de Elche, according to
human ethic guidelines from the institution (Grasso S, et al., 2013,
under revision). All cell lines were maintained in DMEM and
supplemented with 10% heat-inactivated fetal bovine serum (FBS),
2 mM glutamine, 1 mM sodium pyruvate, 10 mMHEPES, 50 U/ml
of penicillin, and 50 mg/ml streptomycin, and incubated at 37°C in a
humidified 5% CO2/air atmosphere. Primary cell culture samples
were obtained from colorectal tumours excised to patients at the
Hospital Clínico Universitario Virgen de la Arrixaca (Murcia, Spain)
with signed written informed consent, according to institutional
human ethical guidelines. Surgical samples were digested with 1.5 U/ml
dispase, 0.09 mg/ml collagenase II, 0.1 mg/ml pronase E, and 45 U/ml
hyaluronidase and incubated at 37°C for 30 minutes. Fragments were
incubated with RBC lysis solution (GeneAll Biotechnology, Seoul,
Korea) for 10 minutes to eliminate erythrocytes, washed with PBS,
filtered through a 70 μm mesh, washed with PBS, and harvested in
DMEM-F12 containing 20% heat-inactivated FBS, 2 mM glutamine,
10μg/ml insulin, 5.5μg/ml transferrin, 6.7 ng/ml selenium, 0.5μg/mL
hydrocortisone, 20 ng/ml epidermal growth factor, 1 mM sodium
pyruvate, 10mMHEPES, 50U/ml penicillin, 50mg/ml streptomycin,
2.5 μg/mL amphotericin B, and 50 μg/ml gentamicine.
MTT Assay
Cells were treated with Selumetinib or DMSO for 72 hours and
incubatedwith 5mg/mlMTT at 37°C for 3 hours. The formazan crystals
formed were solubilized with DMSO and absorbance was measured at
570 nm using a microplate reader (Anthos 2001, Wals, Austria).
Colony Formation Assay in Soft Agar
Cells were suspended in 0.36% agar containing appropriate
medium and either Selumetinib or DMSO over a 0.6% solidified agar
base layer. After 14 days of incubation, cells were stained with
iodonitrotetrazoluim violet and colonies larger than 100 μm were
counted with an image scanner (Image Scanner III) and the Image
Quant TL software (GE Healthcare).
Mutational Analysis
DNA was extracted from cells using the QIAamp DNA minikit and
the QiaCube automatic nucleic acid extractor (Qiagen, Hilden,
Germany). DNA sequence fragments containing the BRAFV600E
mutation were amplified and injected into a preheated reverse-phase
column (Helix DVB; Varian Analytical Instruments, Walnut Creek,
CA) in a Helix ProStar denaturing high-performance liquid chroma-
tography (dHPLC) instrument (Varian Analytical Instruments) [15].
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after amplification of the corresponding DNA fragments [16]. Presence
of PIK3CA mutations in exons 9 and 20 were determined by direct
sequencing after a nested PCR reaction. Amplicons were purified using
the QiAquick 96 PCR purification kit (Qiagen) and subjected to direct
sequencing using the primers PI542-5IF and PI542-5IR for exon 9 and
PI1047IF and PI1047IR for exon 20. Analysis was performed using a
four-capillary automated sequencer (ABI Prism 3130Genetic Analyzer;
Applied Biosystems, Foster City, CA) [16].
Cell Cycle Analysis
Cells were collected and fixed with chilled 70% ethanol in PBS at
−20°C for at least 30 minutes. Following fixation, cells were
resuspended in PBS containing 0.5% Triton X-100, 25 μg/mL
RNase A, and 25×10−3 μg/mL propidium iodide and analysed using
a flow cytometer (BD FACSCanto™, Becton Dickinson & Co.,
Franklin Lakes, NJ).
Western Blot Analysis
Cells were lysed in a lysis buffer (50 mM Tris pH 7.4, 1% NP40,
150 mM NaCl, 40 mM NaF, 1 mM Na3VO4, 1 mM PMSF),
and 10 μg/ml of protease inhibitor cocktail (Sigma-Aldrich) for
30 minutes on ice. Protein concentration was determined by the
Bradford method (Bio-Rad, Richmond, CA). Total protein content
was fractioned by SDS-PAGE and transferred onto nitrocellulose
membranes, which were subsequently blocked with 5% nonfat dry
milk for 1 hour. Membranes were then incubated overnight with the
indicated primary antibodies. Hsp90 antibody was purchased from
Santa Cruz Biotechnology (Santa Cruz, CA); phospho ERK1/2,
ERK1/2 (Thr202/Tyr204), phospho AKT (Ser473), AKT, phospho
p70S6K (Thr389), p70S6K, phospho RPS6 (Ser235/Ser236), RPS6,
phospho RSK (Ser380), RSK, phospho mTOR (Ser2481), and
mTOR antibodies were purchased from Cell Signaling Technologies
(Beverly, MA); β-actin was purchased from Sigma-Aldrich. Mem-
branes were incubated with horseradish peroxidase-linked secondary
antibodies (GE Healthcare, Buckinghamshire, UK). Protein bands
were detected using the ECL system (GE Healthcare). Densitometric
analyses were performed using Scion Image software.
p70S6K Gene Expression Silencing
A smart pool siRNA for p70S6K or control siRNA (Applied
Biosystems, Carlsbad, CA)were transfected into cells usingOpti-MEMI
Reduced Serum medium (Gibco, Life Technologies Corporation,
Carlsbad, CA) and Lipofectamine RNAiMAX (Invitrogen Technologies
Corporation), according to the manufacturer's instructions. After
48 hours of transfection, cells were treated with DMSO or Selumetinib
and harvested for subsequent experiments.
Real-Time Quantitative RT-PCR
Total RNA from cells was isolated using the TRI reagent
(Sigma-Aldrich) and reverse transcription was performed using the
TaqMan Reverse Transcription Reagents kit (Applied Biosystems). To
eliminate potential DNA contamination, total RNA was treated with
RQ1 DNase (Promega Corp., Madison, WI) for 30 minutes at 37°C,
followed by 2 minutes at 94°C. Real-time quantitative PCR was
performed to amplify 15 ng of cDNA using the ABI PRISM 7700
Sequence Detector System (Applied Biosystems). Taqman probes were
labeled with 6-FAM in 5′ end as the reporter dye, and with a non
fluorescent quencher dye in 3′ end. Glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) was used as endogenous reference in
multiplex PCR. S6KBP1 mRNA relative gene expression in CRC cell
lines was calculated by the comparative Ct method referred to the
GAPDH mRNA housekeeping gene expression.
Statistical Analysis
The experiments were performed with n ≥3 and the data is presented
as mean ± standard error of the mean (SEM). Statistically significant
differences were estimated from P b .05 and evaluated using the
Student t test. Statistical analyses were conducted using GraphPad
Prism version 5 (GraphPad Software Inc., San Diego, CA). The E-bliss
model [17,18] was utilized to analyze the interaction between
Selumetinib and PF-4708671. A theoretical curve (bliss) was calculated
by using the following equation: E bliss = EA + EB – EA × EB, where EA
and EB are the effects of drug A and drug B, respectively, expressed as
the fractional inhibition between 0 and 1. E experimental (E exp) is the
actual result obtained by combination of both drugs. When E bliss is
equal to E exp, the combination is considered additive. If E bliss is more
than E exp the combination is synergistic. On the other hand, if E bliss
is less than E exp, the combination is antagonistic.
Results
Effects of Selumetinib on Cell Proliferation and
Colony Formation
We first analyzed the antiproliferative effect of Selumetinib on a
panel of CRC cell lines by proliferation assays, under anchorage-
dependent growth conditions. On the basis of their varied response
(Figure 1A), we ranked them in sensitive (IC50 ≤1 μM) and resistant
(IC50 N1 μM) cell lines (Table 1). SW620, SW480, HT-29, and LS
174 T cells were sensitive to Selumetinib, whereas HGUE-C-1,
Caco-2, HCT-15, and DLD-1 were highly resistant. The IC50 of
normal non-tumour fibroblasts for Selumetinib is N10 μM (data not
shown). Due to some concerns published with techniques that
employ formazan salts such as MTT [19], we routinely perform
crystal violet assays in addition to MTT assays, and we have not found
significant differences when using both assays under these conditions
(data not shown). We next performed soft agar assays to monitor the
anti-tumour activity of Selumetinib under anchorage-independent
growth conditions (Figure 1B). There was a significant reduction in
colony formation after Selumetinib treatment (1 μM) in the sensitive
LS 174 T and HT-29 cell lines (98.1% and 98.8%, respectively),
whereas in the resistant DLD-1 and HCT-15 cell lines we observed a
minor reduction in colony number (26.8% and 20.8 %, respectively).
These results are in accordance with the effect on anchorage-dependent
cell growth (Figure 1A).
Effects of Selumetinib on Cell Cycle
To investigate whether the antiproliferative effects of Selumetinib
were caused by cell cycle arrest or induction of cell death, we analyzed
cell cycle profiles after treatment for several times (Figure 2,
Supplementary Figure 1 and Supplementary Table 1). Selumetinib
treatment of sensitive cell lines led to an arrest in the G1 phase of the cell
cycle, which was sustained through 72 hours. Comparatively, when the
resistant cell lines were treated with Selumetinib, no apparent arrest in
any of the cell cycle phases was appreciated. Interestingly, the resistant
HCT-15 cells exhibited a transient delay in the G1 phase at 24 hours,
with a subsequent escape and progression into S and G2/M after
48 hours. There was no detectable cell death (SubG1 peak) except for
AB
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Figure 1. Effect of Selumetinib on proliferation and cell colony formation in colorectal cancer cell lines. (A) Cell proliferation assays. CRC
cell lines were treated with increasing doses of Selumetinib for 72 hours. Cell proliferation was measured using the MTT method as
described in Materials and Methods. Values represent the mean ± SEM of at least three independent assays performed in sextuplicate.
(B) Soft agar assays. CRC cells were seeded over agar plates in the presence of DMSO (control), 0.1 μM, or 1 μM Selumetinib and the
colonies formed were stained and counted after 14 days. Each treatment was performed in triplicate, represented as percentage of
control and error bars are the S.E.M.
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death, which was maintained for 72 hours. Same results were obtained
when we performed cell cycle analyses using 500 nM Selumetinib
instead of 1 μM (data not shown).Table 1. Effect of Selumetinib on Cell Proliferation.
Selumetinib Effect on Cell Proliferation
Cell line IC50 (μM) % Inhibition (10 μM)
HT-29 0.033 71.97±1.68
COLO 201 0.034 87.93±1.68
SW620 0.121 62.35±5.96
SW480 0.422 70.69±2.63
HCT 116 0.437 58.35±6.59
LS174T 0.771 62.21±2.18
LoVo 7.357 52.18±4.91
Caco-2 N1 26.16±3.85
HCT-15 N1 26.87±3.21
DLD-1 N1 26.37±6.23
HGUE-C-1 N1 11.01±1.39
COLO 320HSR N1 24.16±4.83
IC50 values and percentage of inhibition of cell proliferation in CRC cell lines. The table shows the
IC50 values obtained for each cell line as well as the % inhibition of cell proliferation when the cells
were treated with 10 μM Selumetinib. Cells were classified according to their IC50 value in
Selumetinib-sensitive (IC50 ≤1 μM) and Selumetinib-resistant (IC50 N1 μM). The percentage (%)
of inhibition at 10 μM for each cell line represents the average of at least 3 experiments ± SEM. Each
experiment was performed in sextuplicate (n = 6).Association Between Basal Levels of p-ERK1/2 or Inhibition of
ERK1/2 With Sensitivity to Selumetinib
With the aim of identifying molecular markers of resistance to
Selumetinib, we first determined whether there was a correspondence
between basal phosphorylation levels of ERK1/2 after serum
starvation and resistance. Cell lines with elevated ERK1/2 activity
would be more dependent on the RAF/MEK/ERK pathway for
growth and survival, and hence more sensitive to the MEK inhibitor
Selumetinib. We found that ERK1/2 was highly phosphorylated in
HGUE-C-1 and Caco-2 resistant cells, but not in HCT-15 and
DLD-1 resistant cells (Figure 3, A and B), suggesting that the degree
of basal activation of ERK1/2 is not a predictor of sensitivity to
Selumetinib. We next assessed whether inhibition of MEK1/2 would
be a reliable determinant to predict sensitivity. Therefore, we analyzed
the phosphorylation levels of ERK1/2 after Selumetinib treatment
(Figure 3C). Interestingly, the level of ERK phosphorylation was
suppressed to the same degree in the resistant and sensitive cell lines
after different time treatments.
Association Between KRAS, BRAF, and PIK3CA Mutational
Status and Selumetinib Sensitivity
To determine whether sensitivity correlates with specific genetic
alterations, we analysed the mutational status of KRAS, BRAF, and
PIK3CA genes in a panel of 12 CRC cell lines (Table 2). There is
no evident association between the distribution of PI3KCAmutations
and sensitivity to Selumetinib, as both sensitive and resistant cell lines
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Figure 2. Effect of Selumetinib on cell cycle distribution. (A) Sensitive and (B) resistant CRC cell lines were treated with DMSO or 1 μM
Selumetinib (AZD) for 24, 48, and 72 hours, and cell cycle distribution was determined by flow cytometry, as described in Materials and
Methods, The percentage of cells in each phase of the cell cycle is represented as the average of at least three separate experiments.
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mutations is most likely unrelated to the fate of the cells, as the
sensitivity of the KRAS mutant cell lines to Selumetinib varies
drastically; some of the KRAS-mutant cell lines respond to
Selumetinib, whereas others do not (Table 3). In addition, there is
not a clear association between BRAF mutational status and
Selumetinib response, as the most sensitive cell lines (HT-29 and
Colo-201) exhibit BRAF mutations. Only when we consider the
presence of mutations in the three genes at the same time, a
significant association between these mutations and sensitivity toSelumetinib can be found (Table 3). However, the series used in this
study is too small to draw definite conclusions.
Effect of Selumetinib on RSK, AKT, S6K, and
RPS6 Phosphorylation
As p90RSK is a downstream ERK target and has been reported
as a potential link between the RAS/RAF/MEK/ERK and the
PI3K/AKT/mTOR/S6K pathways [20,21], we sought to deter-
mine the effect of Selumetinib in RSK phosphorylation and found
that RSK phosphorylation levels decreased in both sensitive and
Table 2. Mutational Status of KRAS, BRAF, and PIK3CA Genes in Colorectal Cancer Cell Lines.
Mutational Status
Cell line KRAS (exon 1) BRAF (exon 15) PIK3CA (exon 9 and 20)
HT-29 WT V600E P449T
COLO 201 WT V600E WT
SW620 G12V WT WT
SW480 G12V WT WT
HCT 116 G13D WT H1047R
LS174T G12D WT H1047R
LoVo G13D WT WT
CaCo-2 WT WT WT
HCT-15 G13D WT E545K/D549N
DLD-1 G13D WT E545K/D549N
HGUE-C-1 WT WT WT
COLO 320HSR WT WT WT
DNA from CRC cell lines was extracted and fragments were amplified by PCR. Presence of KRAS
mutations in exon 1, BRAF mutations in exon 15, and PIK3CA mutations in exons 9 and 20 were
determined by dHPLC or direct sequencing of amplified DNA fragments, as described in Materials
and Methods.
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AKT phosphorylation was not altered in most cell lines except for
HCT-15 and HGUE-C-1 cells, where it appears to be a slight
increase in phosphorylation at 2 hours that was not maintained
after 24 hours of treatment (data not shown). However,
Selumetinib had an obvious impact on the phosphorylation of
S6K (p70 and p85 isoforms) and RPS6 in the sensitive but not in
Selumetinib-resistant cells (Figure 4A–C) that was sustained even
after 24 hours of treatment (Figure 4, D–F), whereas no
changes were observed in resistant cells. Curiously, in the resistant
HCT-15 cells, an increase in phosphorylation was observed. The
sensitive cell line LS 174 T, however, showed an intermediate
type of response, as Selumetinib treatment caused a decrease in
RPS6 phosphorylation levels but not in S6K phosphorylation.
This may be because these cells have an IC50 close to 1 μM
(0.771 μM), the cut-off point for considering a cell line as resistant
or sensitive (Table 1).
HGUE-C-1, Caco-2, and DLD-1 Resistant Cells Exhibit High
Basal Levels of Phosphorylated p70S6K and RPS6
To explore whether resistant cells exhibit high constitutive activity
of p70S6K and/or RPS6, we analysed the basal phosphorylationTable 3. Associations Between Presence of KRAS, BRAF, and PIK3CA Mutations and
Sensitivity/Resistance to Selumetinib.
Mutations Total
N° (%)
Selumetinib (cut off IC50=1 μM)
Sensitive
N° (%)
Resistant
N° (%)
P value
BRAF mut 2 (16.67 %) 2 (16.67%) 0 (0%)
BRAF WT 10 (83.34%) 5 (41.67%) 5 (41.67%) 0.4697*
KRAS mut 7 (58.33%) 5 (41.67) 2 (16.67%)
KRAS WT 5 (41.67%) 2 (16.67%) 3 (25%) 0.5581*
PIK3CA mut 5 (41.67%) 3 (25%) 2 (16.67%)
PIK3CA WT 7 (58.34%) 4 (33.34%) 3 (25%) 1*
3 mut 9 (75%) 7 (58.34%) 2 (16.67%)
3 WT 3 (25%) 0 (0%) 3 (25%) 0.0455*
Univariate analysis of associations between presence of mutations and sensitivity/resistance to
Selumetinib was performed using the Fisher's exact test. Number of cases (cell lines) and percentage
(in parenthesis) is shown. The P values are indicated (P b .05 was significant).status of p70S6K and RPS6 after serum starvation (Figure 4, G–J).
Interestingly, HGUE-C-1, Caco-2, and DLD-1 resistant cell lines
expressed high levels of endogenous phosphorylated p70S6K and
RPS6, indicating high constitutive activation of these proteins. In
Caco-2 cells, the p70S6K endogenous phosphorylation was only
moderate. In contrast, in the sensitive cell lines the phosphorylation
status of p70S6K and RPS6 was barely detectable, except for LS 174
T cells, which as indicated earlier, show a “mixed” or intermediate
response. Altogether, these results suggest that Selumetinib resistance
is associated with phosphorylation and hence, endogenous activation
of p70S6K and RPS6 in HGUE-C-1, Caco-2, and DLD-1 cells.
Interestingly, the phosphorylated p70S6K and RPS6 levels in serum-
starved HCT-15 cells were minimal and comparable to those found in
sensitive cells.
Effect of Selumetinib in Primary Cultures from
Colorectal Tumours
Similar studies were performed in primary cultures derived
from patients with CRC. Some of these primary cultures were
sensitive to Selumetinib (HCUVA-CC-34) and others were
resistant (HCUVA-CC-58), as measured under anchorage-dependent
and independent growth conditions (Figure 5, A and B). As
shown in Figure 5C, in the Selumetinib-resistant cells, no
alteration was observed in phosphorylation levels of p70S6K and
RPS6 after Selumetinib treatment. In contrast, when the sensitive
cells were incubated with Selumetinib, a marked decrease in
phosphorylation levels of these proteins was observed, confirming
a strong association of lack of inhibition of p70S6K and RPS6 and
resistance in primary cell cultures. Also, as it was shown with
established cell lines, we were not able to find an association
between the mutational status of KRAS, BRAF or PI3KCA genes,
and resistance to Selumetinib in these primary cell cultures
(Figure 5D). Since some primary cultures were not as sensitive
as established cell lines to Selumetinib, we had to use higher
concentrations, but always within the same range, being 10 μM the
highest concentration used.
p70S6K and RPS6 Phosphorylation Inhibition Reverses
Selumetinib Resistance
Selumetinib was combined with agents that inhibit p70S6K and
RPS6 in order to investigate whether this combination could
potentially overcome resistance to Selumetinib. NVP-BEZ235, a
dual PI3K and mTOR inhibitor that indirectly inhibits p70S6K
and RPS6 [22–24], suppressed both p70S6K and RPS6
phosphorylation in HGUE-C-1 and DLD-1 resistant cells
(Figure 6A and Supplementary Figure 2). However, as expected,
NVP-BEZ235 had no effect on ERK phosphorylation (Figure 6A).
Cell proliferation assays (Figure 6B) and cell cycle analyses (Figure 6, C
and D) revealed that HGUE-C-1 and DLD-1 cells were resistant to
Selumetinib when this drug was used as a single agent. Nonetheless,
when Selumetinib was combined with NVP-BEZ235, cells became
sensitised to Selumetinib. It is noteworthy that althoughNVP-BEZ235
alone showed some effect on HGUE-C-1 and DLD-1 cell growth, the
combinatory effect was significantly greater compared with the sum of
the effects of each drug used alone.
Then, we performed cell proliferation assays using Rapamycin, a
specific mTOR inhibitor and found similar results (Supplementary
Figure 3). In fact, we have confirmed that Rapamycin was also able to
resensitise resistant cells to Selumetinib.
852 Role of p70S6K and RPS6 in Selumetinib Resistance Grasso et al. Neoplasia Vol. 16, No. 10, 2014We next performed the same type of study using the specific
p70S6K inhibitor PF-4708671, which has shown to prevent the
p70S6K-mediated phosphorylation of RPS6 [25]. First, we per-Figure 4. Effect of Selumetinib on RSK, AKT, p70S6K, and RPS6 phosp
left untreated (−) with 500 nM Selumetinib for 2 hours (A) and 24 ho
using the appropriate antibodies to determine phosphorylation levels.
of the p-S6K/S6K (B and E) and p-RPS6/RPS6 (C and F) ratio is represen
S.E.M. Basal phosphorylation levels of p70S6K (G) and RPS6 (I) in sen
from serum-starved cells (0.1% FBS for 48 hours) were separated
phospho-specific and total protein antibodies to p70S6K and RPS6. R
shown. Expression of Hsp90 was measured as an internal control. De
is represented as the average of three different experiments. Error bformed cell proliferation assays in the presence of 500 nM
Selumetinib and different concentrations of PF-4708671(10, 20,
and 30 μM) in resistant cell lines and found that PF-4708671 washorylation. Sensitive and resistant CRC cell lines were treated (+) or
urs (D). Cell extracts were obtained and analyzed by Western blot
Hsp90 wasmeasured as an internal control. Densitometric analysis
ted as the average of three different experiments. Error bars are the
sitive and resistant cell lines. Equal amounts of total cellular protein
by electrophoresis and subjected to Western blot analysis with
epresentative blots of at least three independent experiments are
nsitometric analysis of the p-S6K/S6K (H) and p-RPS6/RPS6 (J) ratio
ars are the S.E.M.
Figure 4. (continued).
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utilized (Supplementary Figure 4). Then, we determined the effect of
a fixed concentration of PF-4708671 (30 μM) with different
concentrations of Selumetinib, using the E-bliss model, which
predicts whether the interaction between two compounds can be
synergistic, antagonistic, or additive. In this case, the interaction of
PF-4708671 with Selumetinib is synergistic (E bliss N E exp), especially
at 1, 5, and 10 μM Selumetinib (Supplementary Figure 5).
Furthermore, cell cycle analyses with 30 μM PF-470867 and different
concentrations of Selumetinib (1, 5, and 10 μM) for 24 hours revealed
that PF-470867 could resensitise resistant cells to Selumetinib, as the
percentage of cells in the SubG1 cells significantly increased when
both drugs were combined. Western blot experiments showed that
PF-4708671 suppressed the phosphorylation of RPS6 in all cell lines
tested, but it had no effect on ERK phosphorylation, even at the
highest concentration used (Figure 7A). The increase in S6K
phosphorylation observed after PF-470867 treatment, however, has
been described as a result of inhibiting a negative feedback loop
mechanism [24]. As it is depicted in Figure 7B, the combination of
30 μMPF-4708671 with Selumetinib resensitized resistant cell lines,
as an increase in the SubG1 phase of the cell cycle was observed when
cells were treated with both drugs. However, in the sensitive SW480
cells, the potentiation of the Selumetinib effect with PF-4708671
was not as remarkable.Biological Inhibition of S6K Reverses Selumetinib Resistance
Finally, we wanted to determine whether S6K silencing would
render sensitivity to Selumetinib-resistant cells. Cells were transiently
transfected with a specific siRNA for RPS6KB1 (S6K). S6K knocking
down was monitored by measuring S6K mRNA levels (Figure 8A)
and protein levels (Figure 8B) after transfection. We can observe
that as a result of S6K silencing, S6K mRNA and protein levels
decreased and subsequently, phosphorylated RPS6 levels diminished
as well. Interestingly, S6K down-regulation sensitized HCT-15 and
HGUE-C-1 cells to Selumetinib, as shown in cell proliferation assays
(Figure 8C), where the effect was moderate and in cell cycle analyses,
where the effect was more evident (Figure 8, D and E). This effect
was heightened when S6K silencing was combined with PF-4708671
treatment, as the percentage of cells in the SubG1 phase of the cell
cycle significantly increased (Figure 8, D and E). We have used
30 μM PF-4708671 in these experiments since we have previously
shown (Supplementary Figures 5 and 6) that we achieved the best
results using this concentration.
Discussion
Identification of predictive biomarkers is becoming a pivotal aspect in
the development of targeted therapies. So far, a large number of studies
have addressed the issue of sensitivity to MEK inhibitors, including
Selumetinib. However, the molecular and genetic basis for resistance is
Figure 4. (continued).
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serous carcinoma of the ovary or metastasic melanoma have shown that
some patients responded efficiently to Selumetinib, whereas tumours of
other patients were inherently resistant [26,27]. Therefore, it is
important to identify the underlying mechanisms responsible for
resistance to MEK inhibition to facilitate individualized therapy. Also,
the understanding of the factors that predict and regulate sensitivity to
Selumetinib would enhance its future clinical use and its progression
into later-stage clinical trials.
In this report we have ranked a panel of CRC cell lines in sensitive
(IC50 ≤ 1 μM) and resistant (IC50 N 1 μM) cells (Figure 1 and Table 1).
Ten μM was the maximum concentration used and 1 μM the cut-off
concentration to distinguish between sensitive and resistant. These
values [14,28,29], or even higher [30] have been used by other authors
as well. More importantly, it has been reported that in a phase I clinical
trial, 1 μM of Selumetinib did not exceed the maximum tolerated dose
achieved in the plasma of patients [31]. Both anchorage-dependent and
-independent growth of sensitive but not resistant cell lines was
inhibited after treatment with Selumetinib (Figure 1, Table 1). In
addition, Selumetinib-sensitive cells underwent G1 arrest, whereas
Selumetinib-resistant cells were barely affected by this drug (Figure 2
and Supplementary Figure 1 and Table 1).
Whether BRAF mutation status is an efficient biomarker for MEK
inhibition cancer treatment has not been strictly evaluated and
validated. Previous studies in melanoma cell lines found that BRAFmutation is associated with enhanced sensitivity to MEK inhibition,
when compared with either wild-type cells or cells harbouring a RAS
mutation [32]. It has also been shown that TORC1 suppression
predicts responsiveness to RAF and MEK inhibitors in B-RAF
mutant melanoma [33]. However, in a phase II clinical trial in
patients with melanoma carrying BRAFmutations, tumour regression
was seen only in some patients, which indicates that BRAF mutation
“per se” cannot predict sensitivity to Selumetinib [11]. Furthermore,
as the frequency of BRAF mutations in CRC is much lower than in
melanoma, the response of BRAF mutated CRC patients to MEK
inhibitors is very low. In our study, we also observed that some but
not all the sensitive cell lines harbour BRAFmutations (Table 2), thus
indicating a weak relationship between BRAF mutational status and
sensitivity to Selumetinib (Table 3).
It is thought that cell lines or tumours with high constitutive
ERK1/2 activity are more dependent on the RAF/MEK/ERK
pathway for cell proliferation and survival, and hence, more sensitive
to growth inhibition by MEK1/2 inhibitors [34]. In this work,
however, we show that basal ERK1/2 phosphorylation levels are
unrelated to the degree of cell growth inhibition accomplished after
Selumetinib treatment. In particular, HGUE-C-1 and Caco-2 cells
with high basal phosphorylation levels of ERK 1/2 (Figure 3, A
and B) are not significantly growth inhibited when treated with
Selumetinib (Figure 1 and Table 1). Furthermore, Selumetinib-
sensitive cell lines exhibit low basal levels, and thus, very weak
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by Selumetinib is not a reliable molecular determinant to predict a
growth-inhibitory response to MEK inhibitors. In fact, Tentler and
coauthors have shown than Mek is not a determinant of sensitivity to
Selumetinib in KRAS-mutated cell lines and suggest that members of
the Wnt pathway may be involved in Selumetinib resistance [35].
In addition, KRAS mutation has been the focus of extensive study
as a predictive marker or response. However, all reports published to
date show that KRAS mutation status alone is not sufficient to
predict response toMEK inhibitors treatment in CRC and other type
of tumours, bringing into question its role as a predictive marker of
response [36–40]. In our study, we found a striking variation in the
response of CRC cell lines and primary cultures derived from
tumours with KRAS mutations to Selumetinib treatment, showing
once again that KRAS mutation do not reliably predict sensitivity to
MEK inhibitors. Thus, the complexity of this link may be due to the
existence of several Ras effector targets, apart from the RAF/MEK/ERK
pathway, that may offer a compensatory route to cell proliferation
and survival.
Mutations in the p110α catalytic subunit of PI3K (PIK3CA)
have been reported in up to 30% CRC [41] and in the last years,
mutations in this gene have been linked to resistance to MEKinhibition. In this study, we found no apparent association
between PIK3CA mutations and resistance to Selumetinib, as
HCT116 and LS 174 T cells harbour both KRAS and PIK3CA
mutations and still are sensitive to Selumetinib treatment. Other
studies have reported that cell lines with mutations in both KRAS
and PIK3CA genes are more resistant to MEK inhibitor treatment
and down-regulation of PIK3CA resensitizes cells to MEK inhibition
[40]. It has also been reported that cell lines that are resistant to
Selumetinib exhibit low or undetectable ERK phosphorylated levels
or show activation of both ERK1/2 and AKT1/2 [37]. Altogether,
these results indicate that resistance to MEK inhibitors seems to be
associated with a biochemical signature rather than a mutation in a
single gene.
As an alternative, we examined whether activation of the PI3K/AKT/
mTOR/p70S6K pathway could have an influence on Selumetinib
resistance. To address this issue, we analysed the endogenous
phosphorylation of AKT1/2, p70S6K, and RPS6 as markers for
activation of the PI3K/AKT/mTOR/p70S6K pathway. Whereas no
relationship was observed between AKT activation and Selumetinib
sensitivity (data not shown), an association between high levels of basal
phosphorylated p70S6K and RPS6 and Selumetinib resistance was
found in HGUE-C-1, Caco-2, and DLD-1 cells (Figure 4). Also, when
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(Figure 5) were treated with Selumetinib, levels of phosphorylated
p70S6K and RPS6 were unaltered, indicating that resistance is
associatedwith high endogenous phosphorylation and lack of inhibition
of p70S6K and RPS6 phosphorylation after Selumetinb treatment. The
use of primary cultures derived from patients is a very powerful
preclinical model, which confirms the findings observed in established
cell lines and serves as an ex vivo treatment for the patients. This
observation prompted us to investigate whether suppression of p70S6K
and RPS6 activity by pharmacologic inhibition using NVP-BEZ235,
Rapamycin or PF-4708671 and biological inhibition using siRNA-
mediated S6K silencing would sensitize resistant cells to Selumetinib.
Very interestingly, we found that p70S6K and consequently, RPS6inhibition sensitized cells to Selumetinib treatment (Figures 6–8 and
Supplementary Figures 2–6).
Surprisingly, in the case of HCT-15 cells, resistance was not
associated with high basal levels of phosphorylated p70S6K and
RPS6, as their constitutive phosphorylation was very low, but
remarkably increased after Selumetinib treatment. This induction
may not be necessary in the other resistant cell lines because p70S6K
and RPS6 are already activated in a constitutive manner. However,
pharmacological and biological inhibition of p70S6K and conse-
quently, RPS6 inactivation, rendered also HCT-15 cells sensitive to
Selumetinib (Figures 7 and 8).
To conclude, advances in the understanding of cancer biology have
led to the development of selective targeted therapies that are aimed to
AB
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selective inhibitor for MEK1/2 that has shown good anti-proliferative
activity in a variety of human CRC cell lines. More recently, a secondgeneration oral MEK inhibitor, Trametinib (GSK1120212) has gained
interest and is under clinical evaluation for the treatment of melanoma
and CRC [42]. Likewise, Selumetinib has entered numerous clinical
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gov/ct2/results?term=AZD6244&Search=Search. However, despite in-
tensive study, the molecular and genetic basis for Selumetinib resistance
remains poorly understood.Thus, identification of predictive biomarkers
of response to Selumetinib is a crucial challenge in cancer drug
development, as it may help to recognize a molecular profile of patient's
tumours to guide appropriate therapeutic choices, according to the most
likely to respond to chemotherapy. In order to properly select patients,
we propose to determine p70S6K and/or RPS6 endogenous activation
previously to treatment, as it may be one of the causes of inefficacy of
MEK inhibitors in some types of solid tumors, including CRC.
Furthermore, these findings provide a strong rationale for the
combination of Selumetinib and p70S6K inhibitors in cancers with
high basal phosphorylation levels and hence, constitutive activation of
p70S6K and RPS6. In this light, it will be important in future studies to
explore whether combination therapy with Selumetinib and p70S6K
and/or RPS6 inhibitors will be able to revert Selumetinib resistance in
animal models, before we can proceed to prove the efficacy of these
treatments in patients.
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